ULTRAGENYX PHARMACEUTICAL INC. Number of Reportable Segments
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for the quarter ending 2024-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for the quarter ending 2023-03-31 was 1.00 Segment.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for fiscal 2023 was 1.00 Segment.
- ULTRAGENYX PHARMACEUTICAL INC. number of reportable segments for fiscal 2021 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-02-18 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-19 | |||
| 2024-09-30 | 1.00 Segment 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | 1.00 Segment 10-Q · filed 2024-08-02 | |||
| 2024-03-31 | 1.00 Segment 10-Q · filed 2024-05-03 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-02-21 | |||
| 2023-09-30 | 1.00 Segment 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | 1.00 Segment 10-Q · filed 2023-08-04 | |||
| 2023-03-31 | 1.00 Segment 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2023-02-17 | |||
| 2016-09-30 | 1.00 Segment 10-Q · filed 2016-11-08 | |||
| 2016-06-30 | 1.00 Segment 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | 1.00 Segment 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |